State-by-State NP Prescribing Authority for GLP-1s: The Employer Compliance Guide

GLP-1 medications like semaglutide and tirzepatide aren't DEA-controlled substances, so the question of whether a nurse practitioner can prescribe them isn't governed by drug scheduling the way it is for something like phentermine. The real gating factor is the NP's general prescriptive authority under their state's Nurse Practice Act, plus a small but growing number of state-specific rules written specifically in response to the GLP-1 boom. For employers placing or supervising NPs who prescribe weight-loss medication, both layers matter, and missing either one creates real compliance exposure.

A note before going further: this is not legal advice, and the laws covered here are moving quickly. Treat this as a framework for the questions to ask, not a final answer for any specific hire. Verify current status against the AANP's interactive State Practice Environment map and your own counsel before making a placement decision.

Why GLP-1s are a distinct compliance question

Weight-loss prescribing draws more regulatory scrutiny than most other prescribing categories, partly because of a history of "diet pill mill" enforcement actions that predates GLP-1s entirely. Regulators in several states watch this category specifically, separate from how they treat general primary care prescribing. That means an NP's general scope of practice answers most of the question, but not all of it. A facility needs to check both the NP's underlying practice authority and whether the state has layered any obesity-specific or weight-loss-clinic-specific rules on top of it.

The three-tier framework that determines baseline authority

Every state falls into one of three categories defined by the American Association of Nurse Practitioners:

Full Practice Authority (FPA) states let NPs evaluate, diagnose, and prescribe, including GLP-1s, without a mandated physician relationship. As of 2026, roughly two dozen states plus Washington, D.C. fall into this category, though the exact count depends on the source and the date, since several states have moved into this category just in the past few years and at least one more is mid-transition. States that have held FPA status for an extended period and are unlikely to be in flux include Arizona, Washington, Oregon, Colorado, Montana, Wyoming, New Mexico, Maryland, and Nevada. Even in FPA states, it's worth noting that some FPA designations carry hour or continuing-education thresholds before independence applies. Illinois, for example, requires NPs to log at least 4,000 clinical hours and 250 hours of continuing education before they qualify for full, independent prescribing, including controlled substances.

Reduced Practice states require a career-long collaborative agreement with a physician for prescribing, though the NP retains more autonomy than in restricted states. New York falls here: NPs need a written collaborative agreement with a physician, or must have logged 3,600 practice hours to apply for independence under the state's NP Modernization Act. Pennsylvania requires a collaboration agreement for every NP regardless of experience, and the collaborating physician's name appears directly on the prescription.

Restricted Practice states require ongoing physician supervision or delegation for prescribing. Texas requires every NP to have a Prescriptive Authority Agreement with a Texas-licensed physician, including for GLP-1 prescribing, often with monthly quality review and chart audits built into the agreement. Florida requires supervising-physician protocols for NPs, and even Florida's limited "Autonomous APRN" registration, available only to primary care NPs, doesn't remove that requirement for this category.

State-specific rules that go beyond general scope of practice

This is the layer that's easy to miss if an employer only checks general NP practice authority and assumes that answers the GLP-1 question.

Mississippi banned off-label GLP-1 prescribing for weight loss as of August 2023. Practically, that means a prescriber, NP or physician, can prescribe semaglutide to a diabetic patient under its diabetes indication, but cannot prescribe a diabetes-indicated GLP-1 off-label purely for weight loss. Only FDA-approved obesity formulations are permitted for that purpose, and using the wrong formulation for the wrong indication can trigger board discipline.

Florida treats controlled and non-controlled weight-loss drugs differently for telehealth specifically. GLP-1s, since they aren't controlled, can be prescribed via telehealth with a proper exam. Phentermine, a Schedule IV controlled substance, cannot, since weight management isn't on Florida's list of telehealth exceptions for controlled substances. An NP operating a multi-state telehealth weight-loss program needs to track this distinction drug by drug, not just state by state.

California's Corporate Practice of Medicine doctrine adds a business-structure layer on top of clinical scope of practice. Even an NP with independent prescribing authority may not be able to own or operate a weight-loss clinic without a physician involved at the ownership or business-entity level. This is a separate question from whether the NP can clinically prescribe, and it's easy to satisfy the clinical question while still being out of compliance on the business structure.

New York has specific sourcing rules for compounded GLP-1s: they must come from FDA-registered or New York-licensed pharmacies operating under 503A or 503B standards. This matters more than it might initially seem, given how much of the compounded GLP-1 market has grown alongside brand-name shortages.

A practical compliance checklist for employers

Before placing or supervising an NP in a GLP-1-prescribing role, a few questions are worth running through directly:

Does the NP's state grant full, reduced, or restricted practice authority, and does that status come with hour or CE thresholds that affect this specific NP?

If a collaborative or supervisory agreement is required, is it in place, current, and does it specifically address weight-management prescribing?

Does the state have any obesity-specific prescribing rules, like Mississippi's off-label restriction, that apply regardless of the NP's general scope?

If the practice is structured as a weight-loss clinic or med spa, does the business entity itself need a physician owner or medical director, separate from the clinical supervision question?

And if any compounded GLP-1s are involved, is the source pharmacy properly registered under the relevant state and federal standards?

One more practical note worth flagging to employers directly: even in full practice authority states where no legal requirement exists, some insurers and pharmacies still request physician involvement for prior authorization on high-cost branded GLP-1s. That's not a licensing issue, but it can functionally slow down a workflow that looks compliant on paper.

Frequently asked questions

Are GLP-1 medications controlled substances?

‍No. Semaglutide and tirzepatide are not DEA-scheduled. This distinguishes them from older weight-loss drugs like phentermine, which is Schedule IV and carries its own DEA registration and prescription monitoring requirements separate from general NP scope of practice.

Can a nurse practitioner prescribe GLP-1s independently in any state?

‍In full practice authority states, generally yes, assuming the NP meets any state-specific experience or continuing-education thresholds for independent prescribing. In reduced or restricted practice states, the NP needs an active collaborative or supervisory agreement with a physician, and that agreement should specifically cover weight-management prescribing.

Does a state's general NP scope of practice automatically cover GLP-1 prescribing?

‍Mostly, but not entirely. A handful of states, Mississippi being the clearest example, have obesity-specific prescribing rules that apply on top of general scope of practice. Employers should check both layers rather than assuming general practice authority settles the question.

Where can employers verify current state-by-state status?

‍The AANP maintains an interactive State Practice Environment map that's the most authoritative source, and state boards of nursing are the definitive answer for any state-specific question. Given how often this landscape shifts, that verification step shouldn't be skipped for an actual hiring or placement decision.

Need clinicians who are already credentialed and compliant for the states you operate in? Schedule a call with DirectShifts